Abstract:Medical Decision Making, Ahead of Print. BackgroundIn economic evaluations of novel therapies, assessing lifetime effects based on trial data often necessitates survival extrapolation, with the choice of model affecting outcomes. The aim of this study was to assess accuracy and variability between alternative approaches to survival extrapolation.MethodsData on HER2-positive breast cancer patients from the Swedish National Breast Cancer Register were used to fit standard parametric distribution (SPD) models and excess hazard (EH) models adjusting the survival projections based on general population mortality (GPM). Models were fitted using 6-y data for stage I and II, 4-y data for stage III, and 2-y data for stage IV cancer reflecting an early data cutoff while maintaining sufficient events for comparison of model estimates with actual long-term outcomes. We compared model projections of 15-y survival and restricted mean survival time (RMST) to 15-y registry data and explored the variability between models in extrapolations of long-term survival.ResultsAmong 11,224 patients compared with the observed registry 15-y RMST estimates across the disease stages, EH cure models provided the most accurate estimates in patients with stage I to III cancer, whereas EH models without cure most closely matched survival in patients with stage IV cancer, in which cure assumption was less plausible. The Akaike information criterion–averaged model projections varied as follows: −8.2% to +5.3% for SPD models, −4.9% to +5.2% for the EH model without a cure assumption, and −19.3% to −0.2% for the EH model with a cure assumption. EH models significantly reduced between-model variance in the predicted RMSTs over a 50-y time horizon compared with SPD models.ConclusionsEH models may be considered as alternatives to SPD models to produce more accurate and plausible survival extrapolation that accounts for general population mortality.HighlightsExcess hazard (EH) methods have been suggested as an approach to incorporate background mortality rates in economic evaluation using survival extrapolation.We highlight that EH models with or without a cure assumption can produce more accurate survival projections and significantly reduce between-model variability in comparison with standard parametric distribution models across cancer stages.EH models may be a preferred modeling method to reduce model uncertainty in health economic modeling since models that would otherwise have produced implausible extrapolations are constrained by the EH framework.Reduced uncertainty in economic evaluations will enhance the application of evidence-based health care decision making.

Using Clinical Experts Beliefs to Compare Survival Models in Health Technology Assessment

SurvInt: a simple tool to obtain precise parametric survival extrapolations

Bayesian multi-parameter evidence synthesis to inform decision-making: a case study in hormone-refractory metastatic prostate cancer

Optimisation versus certainty: understanding the issue of heterogeneity in economic evaluation

A Bayesian Framework for Patient-Level Partitioned Survival Cost-Utility Analysis

Uncertainty representation for early phase clinical test evaluations: a case study

MPES-R: Multi-Parameter Evidence Synthesis in R for Survival Extrapolation—A Tutorial

Probabilistic choice models in health-state valuation research: background, theories, assumptions and applications

General Population Mortality Adjustment in Survival Extrapolation of Cancer Trials: Exploring Plausibility and Implications for Cost-Effectiveness Analyses in HER2-Positive Breast Cancer in Sweden

Modeling Covariate-Adjusted Survival for Economic Evaluations in Oncology

Bayesian pairwise meta‐analysis of time‐to‐event outcomes in the presence of non‐proportional hazards: A simulation study of flexible parametric, piecewise exponential and fractional polynomial models

An Evaluation of an Algorithm for the Selection of Flexible Survival Models for Cancer Immunotherapies: Pass or Fail?

Advantages of Using the Net-Benefit Approach for Analysing Uncertainty in Economic Evaluation Studies

Impact of limited sample size and follow-up on single event survival extrapolation for health technology assessment: a simulation study

An Introduction to Markov Modelling for Economic Evaluation

Blended Survival Curves: A New Approach to Extrapolation for Time-to-Event Outcomes from Clinical Trial in Health Technology Assessment

Capturing Valuation Study Sampling Uncertainty in the Estimation of Health State Utility Values Using the EQ-5D-3L

The Corrective Approach: Policy Implications of Recent Developments in QALY Measurement Based on Prospect Theory

Informing Structural Assumptions for Three State Oncology Cost-Effectiveness Models through Model Efficiency and Fit

Risk aversion and uncertainty in cost-effectiveness analysis: the expected-utility, moment-generating function approach

A Full Bayesian Model to Handle Structural Ones and Missingness in Economic Evaluations from Individual-Level Data